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ABSTRACT: L-Asparaginase (EC 3.5.1.1) was first used as a component of
combination drug therapies to treat acute lymphoblastic leukemia (ALL), a cancer
of the blood and bone marrow, almost 50 years ago. Administering this enzyme to
reduce asparagine levels in the blood is a cornerstone of modern clinical protocols
for ALL; indeed, this remains the only successful example of a therapy targeted
against a specific metabolic weakness in any form of cancer. Three problems,
however, constrain the clinical use of L-asparaginase. First, a type II bacterial
variant of L-asparaginase is administered to patients, the majority of whom are
children, which produces an immune response thereby limiting the time over
which the enzyme can be tolerated. Second, L-asparaginase is subject to proteolytic degradation in the blood. Third, toxic side effects
are observed, which may be correlated with the L-glutaminase activity of the enzyme. This Perspective will outline how asparagine
depletion negatively impacts the growth of leukemic blasts, discuss the structure and mechanism of L-asparaginase, and briefly
describe the clinical use of chemically modified forms of clinically useful L-asparaginases, such as Asparlas, which was recently given
FDA approval for use in children (babies to young adults) as part of multidrug treatments for ALL. Finally, we review ongoing efforts
to engineer L-asparaginase variants with improved therapeutic properties and briefly detail emerging, alternate strategies for the
treatment of forms of ALL that are resistant to asparagine depletion.
Acute lymphoblastic leukemia (ALL) primarily affectsyoung children (2−4 years of age), although it is also
seen in adolescents and young adults.1,2 In this disease, too
many stem cells differentiate into lymphoblasts leading to the
excessive overproduction of leukocytes, which cannot fight
infections,3 and a decreased number of circulating, healthy
white and red blood cells. A serendipitous observation4 led to
the discovery that L-asparaginase, which catalyzes the
hydrolysis of L-asparagine to L-aspartate and ammonia (Figure
1a),5 is the component of guinea pig serum that prevents
lymphoma proliferation.6 Over the 60 intervening years, this
finding has been exploited in the development of clinical
protocols to treat ALL that include injection of L-asparaginase
together with the administration of other anticancer agents,
which now result in a survival rate for childhood ALL of >90%
in the United States.7 On the other hand, serious side effects
associated with L-asparaginase continue to drive studies of
engineered and chemically modified variants of the enzyme
with lower immunogenicity, higher catalytic activity, and
extended half-lives.8 These efforts have led to new forms of the
enzyme, such as Asparlas (calaspargase pegol-mknl), which
received FDA approval in December 2018. In this Perspective,
we will discuss (i) the molecular mechanisms by which
asparagine depletion is thought to impact the growth of
leukemic blasts,9 (ii) the structure and mechanism of L-
asparaginase,10 and (iii) chemically modified forms of type II
Escherichia coli L-asparaginases11 that are used in the clinic. We
also review ongoing efforts to develop L-asparaginase variants
with improved pharmacokinetic properties of the enzyme12
and emerging strategies for the treatment of forms of ALL that
are resistant to asparagine depletion.13
■ ASPARAGINE, CANCER, AND ACUTE
LYMPHOBLASTIC LEUKEMIA
Rapidly dividing cells must obtain the components needed for
the synthesis of proteins, nucleic acids, and lipids. Their pace
of growth is constrained, however, by the availability of these
components from either de novo synthesis or the local
environment of the cell.14 For reasons that are not yet clear,
asparagine synthetase (ASNS), the enzyme that synthesizes L-
asparagine from L-aspartic acid,15 plays a key role in the
response to amino acid deprivation.16 Thus, when cells are
deprived of nutrients, the kinase GCN2 phosphorylates
translation initiation factor eIF2α, thereby decreasing the
rate of general protein synthesis (Figure 1b).17 This
phosphorylation also leads to translation of mRNA encoding
ATF4, a transcriptional activator needed for survival, which
leads to upregulation of the gene encoding ASNS among
others.18,19 The importance of ASNS in cancer biology is
highlighted by a number of recent studies. For example,
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silencing the gene encoding ASNS strongly inhibits sarcoma
growth in a mouse model,20 and an increased level of ASNS
expression in a breast cancer cell line is strongly correlated with
subsequent metastatic relapse.21 Presumably, increased levels
of ASNS lead to higher L-asparagine concentrations in the cell,
but exactly why this is important for tumor growth and
metastatic progression remains the subject of ongoing
research.22 Whatever the metabolic basis of these observations,
asparagine depletion, in combination with other anticancer
drugs, such as vincristine, prednisolone, and dexametha-
sone,23,24 is an effective treatment for ALL because leukemic
blasts express ASNS at very low levels. These proliferating cells
are therefore auxotrophic for L-asparagine,25 which they must
import from circulating blood. As a result, the presence of
circulating L-asparaginase results in nutritional stress in the
leukemic blasts leading to apoptosis.26
■ CLINICALLY IMPORTANT L-ASPARAGINASES
Humans possess a type III (Ntn-amidohydrolase) L-aspar-
aginase, which requires an N-terminal threonine residue for
catalytic activity27 and is produced by autoproteolytic
activation in a process that is stimulated by glycine.28
Unfortunately, the native human L-asparaginase is poorly
suited for therapeutic applications because it exhibits a
millimolar KM value for L-asparagine.
29 Instead, type II L-
asparaginases from E. coli or Dickeya chrysanthemi (formerly
named Erwinia chrysanthemi)30 are used in treatment protocols
for ALL31 because they eliminate circulating L-asparagine
efficiently and are comparatively easy to produce.12,32 Wild
type (WT) type II L-asparaginases have a strong preference for
L-asparagine as a substrate (KM = 11 μM) and exhibit a low
glutaminase side activity (2−10%). In contrast, the type I L-
asparaginases of bacterial origin hydrolyze L-asparagine (KM =
1 mM) and L-glutamine with similar catalytic efficiencies.33
Some evidence suggests that glutaminase activity is correlated
with toxic side effects, including hyperglycemia, pancreatitis,
and neurological seizures.34 Type I bacterial L-asparaginases
are therefore not used in the clinic.
■ STRUCTURE AND CATALYTIC MECHANISM OF
TYPE II L-ASPARAGINASES
Numerous X-ray crystal structures have been reported for
bacterial type II L-asparaginases, as both the free enzymes and
complexes with small molecules.10,35−49 Enzymes in this family
are homotetramers in their biologically active form with each L-
asparaginase monomer being composed of two domains
(Figure 2a). The four active sites in the tetramer are located
between the N- and C-domains of adjacent monomers and
contain a catalytic triad comprising residues Thr12, Tyr25, and
Asp90 (E. coli numbering) (Figure 2b).49 Although alternate
residues were originally proposed as defining a catalytic
triad,10,50 the geometrical constraints imposed by the need
for any nucleophile to attack the carbonyl amide in the L-
asparagine side chain at an angle of 107° (the Bürgi−Dunitz
angle)51 relative to the plane of the C−O σ-bond support the
view that Thr12 plays a critical role in catalysis.49,50 The ability
of the Thr12 side chain to adopt the correct orientation
relative to the bound substrate is facilitated by its location on a
flexible loop of the enzyme. In addition, the X-ray crystal
structure of the complex between L-aspartate and the T89V
variant of the type II E. coli L-asparaginase shows a covalent
bond between the side chain of Thr12 and the carboxylate
group of the amino acid (Figure 2c).35
Figure 1. (a) Reaction catalyzed by L-asparaginase. (b) Correlation of
ASNS expression under conditions of nutrient starvation. Phosphor-
ylation of eIF2α by GCN2 leads to a reduction of the level of general
protein synthesis and overexpression of the ATF4 transcription factor.
ATF4 then participates in forming an initiation complex, resulting in
transcription of the ASNS gene encoding asparagine synthetase by
RNA polymerase (Pol II). Abbreviations: ATF4, activating tran-
scription factor 4; TATA, TBP binding sequence; CARE, CCAAT
enhancer binding protein-activating transcription factor response
element; C/EBPβ, C/EBP homology protein; TBP, TATA binding
protein; TFIIB, RNA Pol II-associated transcription factor B; TAFs,
TBP-associated factors; GTFs, general transcription factors.
Figure 2. (a) Cartoon representation of the E. coli type II L-
asparaginase tetramer (PDB entry 6PAB).49 α-Helices are colored
from the N- (blue) to C-terminus (red) of one monomer. (b) Close-
up of active site residues (C, teal) of the E. coli type II L-asparaginase/
aspartate (C, yellow) complex. Active site waters, which may play a
role in the transfer of a proton to the general base, are shown as red
spheres. Scheme: N, blue; O, red. (c) Acylated Thr12 (C, yellow)
residue in the active site of the T89V E. coli type II L-asparaginase
variant (C, green) (PDB entry 4ECA).35 Active site waters are shown
as red spheres. Scheme: N, blue; O, red.
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Remarkably, given the plethora of structural data, the
catalytic mechanism employed by type II bacterial L-
asparaginases remains the subject of debate. By analogy with
serine proteases,52 and in light of the acyl−enzyme
intermediate observed by crystallography (Figure 2c),35 it is
generally accepted that hydrolysis proceeds by a double-
displacement mechanism (Figure 3).49,50 This is an interesting
finding in light of the reduced nucleophilicity of secondary
alcohols but is supported by 18O/16O exchange experiments
when β-protonated L-aspartic acid is incubated with the
enzyme.53 In addition, threonine is known to be the active site
nucleophile in the proteasome.54 A network of hydrogen bonds
among Tyr25, Asp90, and active site water molecules mediates
activation of Thr12 for nucleophilic attack (Figure 2b).49,50
Recent experimental55 and computational work,56 however,
has challenged this mechanistic orthodoxy. Thus, it has been
proposed that hydrolysis occurs via direct attack of water,
which is activated by a catalytic triad consisting of Thr12,
Lys162, and Asp90 in the E. coli L-asparaginase. The resulting
tetrahedral intermediate is thought to be stabilized by a second
triad (Thr89, Tyr25, and Glu283) before breaking down to
yield ammonia and L-aspartate. This contentious proposal50 is
inconsistent with the crystallographic observation of an acyl−
enzyme intermediate in the T89V E. coli L-asparaginase
variant35 but is weakly supported by studies of WT guinea
pig L-asparaginase for which an acyl−enzyme intermediate was
not detected during turnover.55
■ PEGYLATED L-ASPARAGINASES: ADVANTAGES
AND DISADVANTAGES
As outlined in the introduction, using WT bacterial type II
enzymes in clinical protocols has a number of disadvantages.
Some of these problems can be mitigated, however, by
attaching polyethylene glycol (PEG) polymers onto surface
lysines of the protein using linkers in a process that is termed
PEGylation (Figure 4a).57−59 The resulting PEGylated
proteins are highly hydrated, with two or three waters solvating
each ethylene glycol unit, increasing both the size and the
hydrophilicity.60 As a result, the proteins are less likely to
aggregate. PEGylation also boosts the half-life of L-asparaginase
in blood, presumably because binding to proteases is precluded
by the steric bulk of the bioconjugate associated with the
external layer of PEG molecules.60 Clinical studies of
Oncaspar, a PEGylated E. coli L-asparaginase in which the
PEG polymers are conjugated by a succinimidyl-succinate
linker (Figure 4b), have shown that this form of the enzyme
has a half-life in blood that is 5-fold longer than that of the WT
enzyme. Oncaspar also appears to be less immunogenic than
unmodified WT E. coli L-asparaginase.61 Of course, this
chemical modification strategy does have drawbacks. For
example, multiple lysine residues adorn the surface of the
enzyme, and attachment of the linker−PEG conjugate
proceeds in a random fashion. As a result, PEGylation often
yields polydisperse L-asparaginase preparations, which can lead
to batch-dependent variations in catalytic activity.62 The
Figure 3. Double-displacement mechanism for asparagine hydrolysis.
Figure 4. (a) Space filling representation of the water-accessible surface of PEGylated E. coli type II L-asparaginase (PDB entry 6EOK)63 showing
the location of lysine residues (blue). One monomer surface is colored green. The PEGylation reaction is also shown. (b) Structures of the linkers
present in Oncaspar (left) and Asparlas (right).
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combined use of nuclear magnetic resonance and X-ray
crystallography offers a strategy for understanding how to
control the extent and location of the modified protein
surface.63,64 “Shedding” PEG molecules from the circulating
PEGylated enzyme due to uncatalyzed hydrolysis of the ester
in the succinimidyl-succinate linker is also a problem.32
Moreover, increasing the half-life of L-asparaginase may raise
blood ammonia levels leading to toxic side effects.
As a relatively new drug developed only for the complicated
multidrug protocols for the treatment of pediatric ALL, it is
reasonable to ask whether Asparlas has significant clinical
advantages compared with other PEGylated forms of L-
asparaginase, such as Oncaspar.65,66 At the time of writing,
the answer seems to depend on the exact clinical protocol that
is being considered. In the protocol developed at the Dana
Farber Cancer Institute,65 the increased hydrolytic stability of
Asparlas, because a succinimidyl-carbamate linker is employed
in PEGylation (Figure 4b),67 means that the drug has to be
administered intravenously only every 21 days rather than the
14-day regimen required for Oncaspar. The more stable linker
in Asparlas also gives this form of PEGylated L-asparaginase a
longer shelf life. On the contrary, inferior outcomes were
observed for Asparlas in an alternate protocol,68 developed by
the Children’s Oncology Group. In addition, the incidence of
hypersensitivity to Asparlas in the combined drug protocol was
>20%, identical to that seen for Oncaspar. Minor side effects,
such as hyperglycemia and hyperbilirubinemia, were also
stronger when Asparlas was given to patients.68
■ L-ASPARAGINASE RESISTANCE
A number of resistance mechanisms have been identified in
clinical studies that limit the effectiveness of L-asparaginase as
an anticancer drug. In addition to the production of
neutralizing antibodies targeted against the bacterial enzymes
and/or the linkers in PEGylated variants, leukemic lympho-
blasts can degrade L-asparaginase thereby potentiating antigen
processing and an immune response.69 Alternatively, depleting
circulating L-asparagine may lead to upregulation of ASNS
expression in lymphoblasts, which leads to drug resistance.13,70
Other adaptive metabolic changes must also occur, however, to
ensure that adequate amounts of glutamine and aspartate are
available for asparagine synthesis,71 resulting in complex
phenotypes. For example, overexpression of the ASNS gene
must be correlated with the coordinated translation of genes
encoding the glutamate/aspartate transporter, glutamine
synthetase, and aspartate transaminase to permit increased
levels of asparagine synthesis (Figure 5).71,72 Protein
degradation may also contribute to the levels of endogenous
asparagine needed for cell growth and proliferation.73 Other
resistance mechanisms have been reported, including L-
asparagine secretion by mesenchymal stromal cells (MSCs)
in the cancer microenvironment. MSCs in bone marrow are
resistant to many drugs but can be killed by vincristine,74
which inhibits microtubule assembly.75 Thus, treating MSCs
with vincristine decreases the L-asparagine concentration in the
microenvironment,76 explaining the reported synergistic effect
of this drug and L-asparaginase in clinical protocols.77,78
■ ENGINEERING THE THERAPEUTIC PROPERTIES OF
L-ASPARAGINASE
With regard to the future, there is substantial current interest
in characterizing the properties of L-asparaginases from all
kingdoms of life to identify those that combine stability and
high catalytic efficiencies that are non-immunogenic and have
reduced glutaminase side activities.44,47,79,80 Structure-based
engineering strategies are therefore being pursued to obtain
human L-asparaginase variants with clinically viable activity and
substantially lower ability to use glutamine as a substrate.
The molecular origin of the asparaginase/glutaminase
selectivity exhibited by type II bacterial L-asparaginases remains
under investigation.46 X-ray crystal structures of D. chrys-
anthemi L-asparaginase bound to L-aspartate show that this
bacterial enzyme has an active site loop that exists in
disordered, “open”, and “closed” conformations.81,82 Thus, as
first proposed by Lubkowski and co-workers,81 substrate
binding gives rise to a conformation in which Thr15
(equivalent to Thr12 in the E. coli enzyme) is correctly
positioned for nucleophilic attack on the side chain amide. In
this model, substrate selectivity is therefore a consequence of
differences in the conformational preferences of this loop after
the enzyme binds to either of the amino acid substrates.
Structures of L-asparaginase bound to L-glutamine or L-
glutamate in a catalytically competent complex that could
test this model, however, have yet to be reported.
Four residues (Ala31, Glu63, Pro123, and Ser254) thought
to mediate changes in loop conformation in the D.
chrysanthemi L-asparaginase were identified on the basis of X-
ray crystallography. A series of single, double, and triple
variants were prepared by site-directed mutagenesis and
characterized for substrate selectivity.46 Although many of
these variants do indeed exhibit lower L-glutaminase activity,
their ability to catalyze the conversion of L-asparagine to L-
aspartate is also considerably impaired. The E63Q D.
chrysanthemi variant, however, shows a 95% decrease in L-
glutaminase activity while retaining 90% of WT L-asparaginase
activity.
In unrelated work, molecular dynamics (MD) simulations
on the E. coli L-asparaginase showed the importance of
enzyme−substrate contacts in facilitating a conformational
change to the active form of the enzyme.83 These calculations
imply that L-glutamine has fewer contacts with every active site
residue when compared to L-asparagine, except Gln59
(equivalent to Glu59 in the Dickeya homologue), Thr89, and
Lys162. The interaction of the α-carboxylate of L-glutamine
with Gln59 has the effect of moving the side chain amide away
Figure 5. L-Asparaginase disrupts the ability of lymphoblasts to
import asparagine, leading to altered glutamine metabolism via
intermediates in the TCA cycle.
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from Thr12 in the E. coli L-asparaginase. Replacing Gln59 with
a leucine residue gives a Q59L L-asparaginase variant, which is
capable of hydrolyzing L-asparagine with 80% of WT enzyme
activity while exhibiting almost undetectable glutaminase
activity.83 Cell-based assays showed that the Q59L L-
asparaginase variant was cytotoxic against cells lacking the
ability to biosynthesize L-asparagine. Subsequent studies using
the Q59L L-asparaginase variant to treat xenografts of the Sup-
B15 leukemia cell line, which does not express ASNS, in
NOD/SCID gamma mice suggested that L-asparaginase
activity alone only delays growth.84 This finding supports the
hypothesis that durable in vivo anticancer activity requires a
low level of L-glutaminase side activity when the enzyme is
administered without other drugs in a microenvironment of
noncancerous cells. Unambiguously resolving the importance
of L-glutaminase activity in the treatment of ALL remains an
important problem in this research area.
■ OUTLOOK
The clinical use of L-asparaginase in treatment protocols is an
important factor in the very successful outcomes experienced
by ALL patients. Developments in linker design and stability,
coupled with more consistent bioconjugation procedures, will
likely improve the solubility and other pharmacokinetic
properties of PEGylated forms of L-asparaginase.8 Evidence
that shows the general importance of L-asparagine in the
growth and proliferation of cancers, such as sarcoma20 and
those of the lung,85 breast,21,86 and prostate,87 is also
accumulating. It therefore seems reasonable to expect that
the effects of including L-asparaginase in new combination
therapies against other forms of cancer will be investigated.
These efforts, however, will not overcome resistance due to
upregulation of ASNS expression or be viable for tumors that
do not require a supply of endogenous asparagine. Alternate
strategies that target ASNS are therefore being discussed.15,88
Unfortunately, although sulfoximine-based inhibitors have
been reported that exhibit high affinities for human
ASNS,89−91 these compounds are poorly bioavailable, and
hence, this therapeutic strategy remains to be validated in
animal models.
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Neto, J., and Polikarpov, I. (2003) Structural comparison of
Escherichia coli L-asparaginase in two monoclinic space groups. Acta
Crystallogr., Sect. D: Biol. Crystallogr. 59, 416−422.
(42) Kravchenko, O. V., Kislitsin, Y. A., Popov, A. N., Nikonov, S. V.,
and Kuranova, I. P. (2008) Three-dimensional structures of L-
Asparaginase from Erwinia carotovora complexed with aspartate and
glutamate. Acta Crystallogr., Sect. D: Biol. Crystallogr. 64, 248−256.
(43) Dhavala, P., and Papageorgiou, A. C. (2009) Structure of
Helicobacter pylori L-asparaginase at 1.4 Å resolution. Acta Crystallogr.,
Sect. D: Biol. Crystallogr. 65, 1253−1261.
(44) Borek, D., Kozak, M., Pei, J., and Jaskolski, M. (2014) Crystal
structure of active site mutant of antileukemic L-asparaginase reveals a
conserved zinc-binding site. FEBS J. 281, 4097−4111.
(45) Tomar, R., Sharma, P., Srivastava, A., Bansal, S., Ashish, and
Kundu, B. (2014) Structural and functional insights into an archaeal
L-asparaginase obtained through the linker-less assembly of
constituent domains. Acta Crystallogr., Sect. D: Biol. Crystallogr. 70,
3187−3197.
(46) Nguyen, H. A., Su, Y., and Lavie, A. (2016) Design and
characterization of Erwinia chrysanthemi L-asparaginase variants with
diminished L-glutaminase activity. J. Biol. Chem. 291, 17664−17676.
(47) Guo, J., Coker, A. R., Wood, S. P., Cooper, J. B., Mahmood
Chohan, S., Rashid, N., and Akhtar, M. (2017) Structure and function
of the thermostable L-asparaginase from Thermococcus kodakarensis.
Acta Crystallogr. Sect. D, Struct. Biol. 73, 889−895.
(48) Maggi, M., Mittelman, S. D., Parmentier, J. H., Colombo, G.,
Meli, M., Whitmire, J. M., Merrell, D. S., Whitelegge, J., and Scotti, C.
(2017) A protease-resistant Escherichia coli asparaginase mutant with
outstanding stability and enhanced anti-leukaemic activity in vitro. Sci.
Rep. 7, 14479.
Biochemistry pubs.acs.org/biochemistry Perspective
https://dx.doi.org/10.1021/acs.biochem.0c00354
Biochemistry XXXX, XXX, XXX−XXX
F
(49) Lubkowski, J., and Wlodawer, A. (2019) Geometric
considerations support the double-displacement catalytic mechanism
of L-asparaginase. Protein Sci. 28, 1850−1864.
(50) Lubkowski, J., Vanegas, J., Chan, W.-K., Lorenzi, P. L.,
Weinstein, J. N., Sukharev, S., Fushman, D., Rempe, S., Anishkin, A.,
and Wlodawer, A. (2020) Mechanism of catalysis by L-asparaginase.
Biochemistry 59, 1927−1945.
(51) Bürgi, H. B., Dunitz, J. D., Lehn, J.-M., and Wipff, G. (1974)
Stereochemistry of reaction paths at carbonyl centers. Tetrahedron 30,
1563−1572.
(52) Dodson, G., and Wlodawer, A. (1998) Catalytic triads and their
relatives. Trends Biochem. Sci. 23, 347−352.
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